No Early Relief for JW Therapeutics from Cancer Wonder Drug

The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down.  Large-scale market expansion is not going to be easy  The company is undervalued compared with its peers pending further progress in commercializing its products By Molly Wen A medical breakthrough is only one milestone on a long and uncertain road to mass…

Read More »